Jeffrey E. Gershenwald
0000-0003-4519-5369
Publication & Citation Trends
Publications
0 total
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.
Cited by 0
Semantic Scholar
The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection
Cited by 0
Semantic Scholar
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Cited by 11
Semantic Scholar
A Refresher on the Key Terminologies and Principles of the American Joint Committee on Cancer (AJCC) Staging System.
Cited by 0
Semantic Scholar
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Cited by 3
Semantic Scholar
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma.
Cited by 4
Semantic Scholar
Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis OA
Cited by 0
Semantic Scholar
Research Topics
Cutaneous Melanoma Detection and Management
(338)
Melanoma and MAPK Pathways
(197)
Cancer Immunotherapy and Biomarkers
(140)
CAR-T cell therapy research
(115)
Immunotherapy and Immune Responses
(104)
Affiliations
Rutgers, The State University of New Jersey
Dartmouth College
Novartis (Switzerland)
Fox Chase Cancer Center
Roswell Park Comprehensive Cancer Center